Literature DB >> 24891183

COL1A1 C-propeptide cleavage site mutation causes high bone mass, bone fragility and jaw lesions: a new cause of gnathodiaphyseal dysplasia?

A M McInerney-Leo1, E L Duncan1,2, P J Leo1, B Gardiner1, L A Bradbury1, J E Harris1, G R Clark1,3, M A Brown1, A Zankl4,5.   

Abstract

Gnathodiaphyseal dysplasia (GDD) is a rare autosomal dominant condition characterized by bone fragility, irregular bone mineral density (BMD) and fibro-osseous lesions in the skull and jaw. Mutations in Anoctamin-5 (ANO5) have been identified in some cases. We aimed to identify the causative mutation in a family with features of GDD but no mutation in ANO5, using whole exome capture and massive parallel sequencing (WES). WES of two affected individuals (a mother and son) and the mother's unaffected parents identified a mutation in the C-propeptide cleavage site of COL1A1. Similar mutations have been reported in individuals with osteogenesis imperfecta (OI) and paradoxically increased BMD. C-propeptide cleavage site mutations in COL1A1 may not only cause 'high bone mass OI', but also the clinical features of GDD, specifically irregular sclerotic BMD and fibro-osseous lesions in the skull and jaw. GDD patients negative for ANO5 mutations should be assessed for mutations in type I collagen C-propeptide cleavage sites.
© 2014 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  ANO5; COL1A1; gnathodiaphyseal dysplasia; osteogenesis imperfecta

Mesh:

Substances:

Year:  2014        PMID: 24891183     DOI: 10.1111/cge.12440

Source DB:  PubMed          Journal:  Clin Genet        ISSN: 0009-9163            Impact factor:   4.438


  7 in total

1.  A novel COL1A2 C-propeptide cleavage site mutation causing high bone mass osteogenesis imperfecta with a regional distribution pattern.

Authors:  T Rolvien; U Kornak; J Stürznickel; T Schinke; M Amling; S Mundlos; R Oheim
Journal:  Osteoporos Int       Date:  2017-09-15       Impact factor: 4.507

2.  Mutations That Alter the Carboxy-Terminal-Propeptide Cleavage Site of the Chains of Type I Procollagen Are Associated With a Unique Osteogenesis Imperfecta Phenotype.

Authors:  Tim Cundy; Michael Dray; John Delahunt; Jannie Dahl Hald; Bente Langdahl; Chumei Li; Marta Szybowska; Shehla Mohammed; Emma L Duncan; Aideen M McInerney-Leo; Patricia G Wheeler; Paul Roschger; Klaus Klaushofer; Jyoti Rai; MaryAnn Weis; David Eyre; Ulrike Schwarze; Peter H Byers
Journal:  J Bone Miner Res       Date:  2018-04-18       Impact factor: 6.741

3.  An example of the utility of genomic analysis for fast and accurate clinical diagnosis of complex rare phenotypes.

Authors:  Polona Le Quesne Stabej; Chela James; Louise Ocaka; Mehmet Tekman; Stephanie Grunewald; Emma Clement; Horia C Stanescu; Robert Kleta; Deborah Morrogh; Alistair Calder; Hywel J Williams; Maria Bitner-Glindzicz
Journal:  Orphanet J Rare Dis       Date:  2017-02-07       Impact factor: 4.123

4.  Ano5 modulates calcium signaling during bone homeostasis in gnathodiaphyseal dysplasia.

Authors:  Xin Li; Lei Wang; Hongwei Wang; An Qin; Xingjun Qin
Journal:  NPJ Genom Med       Date:  2022-08-18       Impact factor: 6.083

5.  High bone mass phenotype in a cohort of patients with Osteogenesis Imperfecta caused due to BMP1 and C-propeptide cleavage variants in COL1A1.

Authors:  E H Campanini; D Baker; P Arundel; N J Bishop; A C Offiah; S Keigwin; S Cadden; E Dall'Ara; N Nicolaou; S Giles; J A Fernandes; M Balasubramanian
Journal:  Bone Rep       Date:  2021-07-01

6.  Whole exome sequencing links dental tumor to an autosomal-dominant mutation in ANO5 gene associated with gnathodiaphyseal dysplasia and muscle dystrophies.

Authors:  T V Andreeva; T V Tyazhelova; V N Rykalina; F E Gusev; A Yu Goltsov; O I Zolotareva; M P Aliseichik; T A Borodina; A P Grigorenko; D A Reshetov; E K Ginter; S S Amelina; R A Zinchenko; E I Rogaev
Journal:  Sci Rep       Date:  2016-05-24       Impact factor: 4.379

Review 7.  The Genetic Architecture of High Bone Mass.

Authors:  Celia L Gregson; Emma L Duncan
Journal:  Front Endocrinol (Lausanne)       Date:  2020-10-29       Impact factor: 5.555

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.